Surgical Vision Announces New Data and Sustainability Activities at European Society of Cataract and Refractive Surgeons Congress


  • Over 30 abstracts will be presented on a range of Johnson & Johnson Vision equipment and IOLs including: TECNIS Synergy® IOL, TECNIS Eyhance® IOL and VERITAS™ Vision System
  • Support ESCRS’ Mission Zero goal through ongoing sustainability efforts
  • Participation in the I-Novation sessions on sustainability, presbyopia and cataract extraction and the I-Novation European leadership panel
  • Organization of the inaugural “Women in Ophthalmology” networking and mentoring session

LONDON, September 6, 2022 /PRNewswire/ — Johnson & Johnson Vision: Surgical Vision*a global leader in eye health and a subsidiary of Johnson & Johnson MedTech[*]*will present new data and participate in a series of events during the next 40e Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) September 16-20, 2022. The congress, which takes place at Milano Congress Center at Milan, Italywill feature a range of groundbreaking data, with more than 30 Johnson & Johnson Vision-supported abstracts accepted for presentation throughout the conference.

The Johnson & Johnson ESCRS booth (#A02/B01) will have live demonstration areas allowing surgeons to experience first-hand the VERITAS™ Vision System, a next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety by providing improved anterior chamber stability during the procedure,1.2 surgeon efficiency by providing high performance cutting efficiency combined with a dual pump mechanism and surgeon comfort by focusing on ergonomic improvements at every point of interaction, potentially reducing physical fatigue during surgery.3-6 Additionally, attendees will be able to participate in a Toric VR simulator experience and explore the full TECNIS® Toric II platform, including TECNIS Eyhance® Toric II, TECNIS Symfony® OptiBlue® Toric II, and TECNIS Synergy® Toric II, alongside of the entire TECNIS family of intraocular lenses (IOL).

“We are delighted to be back at ESCRS this year to showcase our wide range of ophthalmic innovations to our surgical customers.” said Erin McEachrenregional vice president, Europe, Middle East & Africa, Johnson & Johnson Surgical Vision. “We are also delighted to see the considerable attention given to sustainability by ESCRS, as it aligns closely with our own approach to sustainability and our commitment to a healthier planet.”

Sustainability at heart

Creating a sustainable future for all is one of Johnson & Johnson’s top priorities. Aaron Kendrick, Sr. Director, Value Stream Leader Vision, will participate in the inaugural ESCRS 2022 Sustainability Panel. He will explain how Johnson & Johnson is strengthening its sustainability goals in three distinct areas: fighting climate change, reducing waste and protecting natural resources.

  • We are on track to meet our global climate goal of achieving carbon neutrality by 2030seven savings of 48,000 tonnes of CO2 annually through renewable energy and energy efficiency programs.8
  • 100% of Johnson & Johnson Vision’s electricity will also come from renewable sources starting this year,9 and we plan to offset the CO2 emissions from electricity used on the stand.
  • We’re on a mission to limit the contribution of landfills through recycling efforts and innovate the way we produce, transport and dispose of waste responsibly.
  • Our manufacturing plant in the Netherlands has been Zero waste to landfill several years, and we no longer use plastic shipping pouches on European surgical vision orders (excludes Portugal).
  • We created the J&J Vision stand by reusing more than 70% of the materials from the previous stand from the last 3 years, in addition, the stand is made from 50% recycled materials. We also aim to reuse up to 90% of our booth materials after the congress as part of our commitment to limit the use of natural resources and reduce waste.
  • We conserve natural resources by exploring alternative ways to present and produce leaflets and materials, launching “e-Instructions For Use” in markets where they meet regulatory guidelines while ensuring that all paper packaging come from certified sustainable forests.

Other Johnson & Johnson Vision representatives will be participating in events throughout ESCRS 22, including Raj Rajpal, Chief Medical Officer, Johnson & Johnson Vision; MK Raheja, Head of R&D in Surgical Vision and Aaron Kendrick who will participate in the ESCRS I-Novation session on sustainability, presbyopia and cataract extraction which will take place on Friday, September 16, 8:30am-3:30pm CEST at the MiCo Milano congress center.

Foster diversity and inclusion

To further reinforce our commitment to equality and inclusion, Johnson & Johnson Vision will also host our first Women in Women in Ophthalmology networking and mentorship event during ESCRS. 25 influential women who work in the field of ophthalmology will come together to discuss approaches to making the industry more accessible to women, with plans to grow as a network of mentors and mentees over the next few years.

Key scientific abstracts supported by Johnson & Johnson Vision include the following:

A full list is available at

TECNIS Eyhance® Toric II, TECNIS Synergy® Toric II and TECNIS Toric II

  • Clinical evaluation of a new toric intraocular lens with improved intermediate function
  • Rotational stability of a toric monofocal intraocular lens with extended depth of field
  • Comparison of rotational stability between Zeiss AT Lisa 939 and Synergy Toric II for the correction of anisometropia with astigmatism and presbyopia
  • Inter-visit rotational stability of a toric intraocular lens with ground haptics

TECNIS Eyhance® & TECNIS Synergy®

  • Comparison of clinical results with a combination of IOLs with different optical properties (Synergy and Eyhance)
  • Comparison of clinical and patient-reported results of a standard monofocal intraocular lens and a new monofocal intraocular lens with modified optical profile
  • Functional results after bilateral refractive lens exchange with a continuous field-of-view IOL

Symfony by TECNIS® OptiBlue®

  • First real-world experience with new extended depth-of-field IOL with violet light blocker

Educational and interactive sessions

Johnson & Johnson Vision also hosts (and supports through educational grants) a series of educational and interactive sessions designed to spark conversation and provide an opportunity to share, discuss and learn from leading experts in the field of ophthalmology. These include:

  • IME Symposia – Phaco Complex Cases Symposium. Space 2. September 16, 20224:00 p.m. – 5:00 p.m.
  • EuroTimes Satellite Symposium: Lock in Visual Performance with Toric IOLs. Space 4 Bedroom. September 17, 202213:00 – 13:45
  • Symposium IME – IOL for presbyopia Space 2. September 17, 20224:00 p.m. – 5:00 p.m.
  • IME Symposium – Advances in Lenticule Extraction Technology. Space 2. September 18, 20229:30 a.m. – 10:30 a.m.
  • EuroTimes Satellite Symposium: Advances in Refractive Surgery. Brown 2 Bedroom. September 18, 202213:00 – 13:45
  • Cataract surgery consumables durability index (SIDICS). MiCo Suite 1. September 19, 20222:14 p.m. – 5:00 p.m.

About Johnson & Johnson Vision: Surgical Vision*

At Johnson & Johnson Vision: Surgical Vision, part of Johnson & Johnson MedTech, we have a bold ambition: to change the trajectory of eye health around the world. Through our operating companies, we deliver innovations that enable eyecare professionals to create better patient outcomes throughout their lives, with products and technologies that address unmet needs , including refractive errors, cataracts and dry eye. In the communities that need it most, we work collaboratively to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at, follow @JNJVision on TwitterJohnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.

About Johnson & Johnson MedTech

At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, helpful technology and a passion for people to transform the future of medical intervention and empower everyone to live the best life possible. For more than a century, we’ve been driving groundbreaking scientific innovation to address unmet needs and reinvent health. In the fields of surgery, orthopedics, vision and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive and more personalized.

*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Medical Ltd, and subsidiaries of both.

** The Johnson & Johnson MedTech companies include the surgical, orthopedic, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.

© Johnson & Johnson Medical Ltd 2022. All rights reserved.

Reserved for healthcare professionals. Please see the Instructions for Use for a full list of indications and important safety information and contact our specialists if you have any questions.


  1. DOF2021OTH4006 R&D Memo – Design Intent for the VERITAS Vision System
  2. Z370584 VERITAS Operator’s Manual Rev E. page 1-6, 1-8, 1-9, 3-7
  3. DOF2021OTH4005 VERITAS Vision System Features
  4. Honavar SG (2017) Head Up, Heels Down, Perfect Posture: Ergonomics for an Ophthalmologist. Indian J Ophthalmol 65 (8:647-650).
  5. Soueid A, Oudit D, Thiagarajah S, Laitung G (2010) The pain of surgery: pain experienced by surgeons during the operation. Int J Surg 8 (2): 118-120.
  6. DOF2021OTH4004 Ergonomic improvements to the VERITAS foot pedal
  7. Last access July 2022
  8. JJV Data on File 2021. Data Substantiation for Energy Efficiency and Renewable Energy Projects at ACUVUE® Contact Lens Manufacturing Facilities in the United States and Ireland
  9. Last access July 2022.

*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Medical Ltd and their affiliates.
**The Johnson & Johnson Medical Devices companies include the surgical, orthopedic, vision and interventional solutions businesses within Johnson & Johnson’s medical device segment.

SOURCEJohnson & Johnson

Christine E. Phillips